Analysts project a big spike in COPD market as new drugs arrive; Valeant raises $930M in latest asset sale
→ The COPD drug market is expected to grow dramatically over the next decade, hitting $14.1 billion by 2025, according to GlobalData. It was $9.9 billion in 2015. The growth will be fueled by increased diagnoses as well as new bronchodilator drug classes and anti-eosinophilic biologics.
→ Valeant is selling iNova for $930 million. The company is selling off assets in an attempt to reduce large piles of debt acquired under previous CEO Mike Pearson as he went on a deal-making spree. Pearson was replaced by Joseph Papa last year.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters